A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
Tekijät: Slik K, Kurki S, Korpela T, Carpen O, Korkeila E, Sundstrom J
Kustantaja: PUBLIC LIBRARY SCIENCE
Kustannuspaikka: SAN FRANCISCO
Julkaisuvuosi: 2017
Journal: PLoS ONE
Tietokannassa oleva lehden nimi: PLOS ONE
Lehden akronyymi: PLOS ONE
Artikkelin numero: ARTN e0185436
Vuosikerta: 12
Numero: 9
Sivujen määrä: 15
ISSN: 1932-6203
eISSN: 1932-6203
DOI: https://doi.org/10.1371/journal.pone.0185436
Verkko-osoite: 10.1371/journal.pone.0185436
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/26866176
Currently used factors predicting disease recurrence in stage II colorectal cancer patients are not optimal for risk stratification. Thus, new biomarkers are needed. In this study the applicability of ezrin protein expression together with MSI status and BRAF mutation status were tested in predicting disease outcome in stage II colorectal cancer. The study population consisted of 173 stage II colorectal cancer patients. Paraffin-embedded cancer tissue material from surgical specimens was used to construct tissue microarrays (TMAs) with next-generation technique. The TMA-slides were subjected to following immunohistochemical stainings: MLH1, MSH2, MSH6, PMS2, ezrin and anti-BRAF V600E antibody. The staining results were correlated with clinicopathological variables and survival. In categorical analysis, high ezrin protein expression correlated with poor disease-specific survival (p = 0.038). In univariate analysis patients having microsatellite instabile / low ezrin expression tumors had a significantly longer disease-specific survival than patients having microsatellite stable / high ezrin expression tumors (p = 0.007). In multivariate survival analysis, the presence of BRAF mutation was associated to poor overall survival (p = 0.028, HR 3.29, 95% CI1.14-9.54). High ezrin protein expression in patients with microsatellite stable tumors was linked to poor disease-specific survival (p = 0.01, HR 5.68, 95% CI 1.53-21.12). Ezrin protein expression is a promising biomarker in estimating the outcome of stage II colorectal cancer patients. When combined with microsatellite status its ability in predicting disease outcome is further improved.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
